Biomedicines (Jan 2024)

Familial Hypercholesterolemia in the Elderly: An Analysis of Clinical Profile and Atherosclerotic Cardiovascular Disease Burden from the Hellas-FH Registry

  • Christina Antza,
  • Christos V. Rizos,
  • Vasileios Kotsis,
  • George Liamis,
  • Ioannis Skoumas,
  • Loukianos Rallidis,
  • Anastasia Garoufi,
  • Genovefa Kolovou,
  • Konstantinos Tziomalos,
  • Emmanouil Skalidis,
  • George Sfikas,
  • Michalis Doumas,
  • Vaia Lambadiari,
  • Panagiotis Anagnostis,
  • Kimon Stamatelopoulos,
  • Georgia Anastasiou,
  • Iosif Koutagiar,
  • Estela Kiouri,
  • Vana Kolovou,
  • Georgios Polychronopoulos,
  • Evangelos Zacharis,
  • Charalambos Koumaras,
  • Chrysoula Boutari,
  • Haralampos Milionis,
  • Evangelos Liberopoulos

DOI
https://doi.org/10.3390/biomedicines12010231
Journal volume & issue
Vol. 12, no. 1
p. 231

Abstract

Read online

Background: Familial hypercholesterolemia (FH) carries a high risk of atherosclerotic cardiovascular disease (ASCVD). As the population ages, the age-related influence on clinical characteristics and outcomes becomes increasingly pertinent. This cross-sectional analysis from the HELLAS-FH registry aims to explore potential differences in clinical characteristics, treatment, ASCVD, and goal achievement between those younger and older than 65 years with FH. Results: A total of 2273 adults with heterozygous FH (51.4% males) were studied. Elderly FH patients (n = 349) had a higher prevalence of ASCVD risk factors, such as hypertension (52.1% vs. 20.9%, p p n = 1924). They also had a higher prevalence of established ASCVD (38.4% vs. 23.1%, p p p < 0.05), both groups had similar attainment of the LDL-C target (3.7% vs. 3.0%). Conclusions: Elderly FH patients have a higher prevalence of ASCVD, particularly CAD. Despite more aggressive treatment, the achievement of LDL-C targets remains very poor. These results emphasize the importance of early FH diagnosis and treatment in reducing ASCVD.

Keywords